There is increasing evidence for the existence of multiple levels of crosstalk between ERα and HER2 signaling pathways in breast cancers, which lead to tumor progression and therapy resistance (Osborne and Schiff, 2011; Montemurro et al., 2013). This evidence concerns the gene ESR1 and breast cancer.